

Timeline of MEDI4736 Study




Figure 1

Pharmacokinetics of MEDI4736




Figure 2A




Figure 2B

Pharmacokinetics of MEDI4736

Dose of MEDI4736 (mg/kg) IV	Human AUC(inf) (d·µg/mL)	Safety Margin (AUCm/AUC _h)	Actual human C _{max} (µg/mL)	Safety Margin (C _{max} m/C _{max} h)
0.1	6	4733	2.8	1357
0.3	28	1014	8.0	475

Figure 3

MEDI4736 Concentration (Doses: 0.1 to 1 mg/kg Q2W IV)




Figure 4

**MEDI4736 Target Engagement (Doses: 0.1 to 1 mg/kg
Q2W IV)**




Figure 5

MEDI4736 Clinical Activity

MEDI4736 Dose Level	Patient	Tumor Type	Number of Doses Received	Best Response (irRC)	% Change in Tumor Burden
0.1 mg/kg Q2W	1056201004	NSCLC	18+	SD	-47.6%
0.1 mg/kg Q2W	1056201006	NSCLC	11	PD	+50.3%
0.1 mg/kg Q2W	1245501002	NSCLC	3	NE	NE
0.1 mg/kg Q2W	1245501003	Melanoma	8	PD	+55.8
0.3 mg/kg Q2W	1094301002	CRC	5	PD	+>100%
0.3 mg/kg Q2W	1245501006	NSCLC	12+	SD	-60.1%
0.3 mg/kg Q2W	1351901002	NSCLC	1	NE	NE
0.3 mg/kg Q2W	1351901004	NSCLC	11+	SD	-34.1%
1.0 mg/kg Q2W	1056201009	NSCLC	8+	SD	-42.2%
1.0 mg/kg Q2W	1094301003	NSCLC	9+	PR	-83.1%
1.0 mg/kg Q2W	1351901007	Melanoma	8+	PR	-69.1%

*Patient 1056201004 received prophylactic steroids prior to dosing.

Figure 6

MEDI4736 Effect on Tumor Size over Time




Figure 7

MEDI4736 Effect on NSCLC Tumor Size over Time (10mg/kg)




Figure 8





Figure 9A

Best Change in Tumor Size from Baseline by PDL-1 Status
(SCCHN in 10 mg/kg Q2W)



10 mg/kg Q2W Evaluable for 1 Scan
CR+PR including unconfirmed
All = 3/19 (15.8%)
PD-L1+ = 2/3 (66.7%)
5 Early terminations prior to 1 st scan 2 TL not evaluable

Figure 9B

Clinical Activity of Medi4736									
Evaluable Population – 24 Weeks Follow Up – SCCHN									
	CR/PR		ORR (Confirmed CR/PR		Disease Control		(CR+PR+SD>=24 weeks)		
	n/N	%	95% CI	n/N	%	95% CI	n/N	%	95% CI
All subjects									
10 mg/kg Q2W	7/62	11.3	(4.7%-21.98%)	7/62	11.3	(4.7%-21.98%)	9/62	14.5	(6.9%-25.8%)
PD-L-1+ 10 mg/kg	4/22	18.2	(5.2%-40.3%)	4/22	10.2	(5.2%-40.3%)	4/22	10.2	(5.2%-40.3%)
PD-L-1- 10 mg/kg	3/37	8.1	(1.7%-21.9%)	3/37	0.1	(1.7%-21.9%)	4/37	0.1	(3.0%-25.4%)
HPV+									
10 mg/kg Q2W	1/25	4.0	(0.1%-20.4%)	1/25	4.0	(0.1%-20.4%)	1/25	4.0	(0.1%-20.4%)
PD-L-1+ 10 mg/kg	0/7	0.0	(0.0%-41.0%)	0/7	0.0	(0.0%-41.0%)	0/7	0.0	(0.0%-41.0%)
PD-L-1- 10 mg/kg	1/16	6.3	(0.2%-30.2%)	1/16	6.3	(0.2%-30.2%)	1/16	6.3	(0.2%-30.2%)
HPV-									
10 mg/kg Q2W	4/25	16.0	(4.5%-36.1%)	4/25	16.0	(4.5%-36.1%)	5/25	20.0	(6.8%-40.7%)
PD-L-1+ 10 mg/kg	3/12	25.0	(5.5%-57.2%)	3/12	25.0	(5.5%-57.2%)	3/12	25.0	(5.5%-57.2%)
PD-L-1- 10 mg/kg	1/12	8.3	(0.2%-38.5%)	1/12	8.3	(0.2%-38.5%)	1/12	8.3	(0.2%-38.5%)
One prior systemic regimen									
10 mg/kg Q2W	4/13	30.6	(9.1%-61.4%)	4/13	30.0	(9.1%-61.4%)	4/13	30.6	(9.1%-61.4%)
PD-L-1+ 10 mg/kg	3/6	50.0	(11.6%-66.2%)	3/6	50.0	(11.6%-66.2%)	3/6	50.0	(11.6%-66.2%)
PD-L-1- 10 mg/kg	1/7	14.3	(0.4%-57.9%)	1/7	14.3	(0.4%-57.9%)	1/7	14.3	(0.4%-57.9%)
At least 2 prior systemic regimen									
10 mg/kg Q2W	3/48	6.3	(1.3%-17.2%)	3/48	6.3	(1.3%-17.2%)	5/48	10.4	(3.5%-22.7%)
PD-L-1+ 10 mg/kg	1/16	6.3	(0.2%-30.2%)	1/16	6.3	(0.2%-30.2%)	1/16	6.3	(0.2%-30.2%)
PD-L-1- 10 mg/kg	2/29	6.9	(0.8%-22.8%)	2/29	6.9	(0.8%-22.8%)	3/29	10.3	(2.2%-27.4%)

Figure 10